Eton Pharmaceuticals, Inc. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
Eton Pharmaceuticals, Inc. (ETON) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $180.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-03-19
- Eton Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-12-31 was -$1.00K.
- Eton Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-09-30 was $0.00.
- Eton Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-06-30 was $0.00.
- Eton Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-03-31 was $181.00K.
- Eton Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $180.00K, a 0.00% change from fiscal 2023.
- Eton Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $180.00K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2024-12-31 | $180.00K 10-K · filed 2026-03-19 | |||
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$1.00K derived: sum of 2 quarters · filed 2026-03-19 | -$1.00K derived: sum of 3 quarters · filed 2026-03-19 | $180.00K 10-K · filed 2026-03-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $181.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $181.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $181.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |